Finish Line Inc. (NASDAQ:FINL): Citigroup believes Finish Line’s guidance is conservative and views the pullback in shares yesterday as overdone. The firm reiterates a Buy rating on the stock with a $26 price target.
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN): Citigroup believes BioMarin’s 6.5M share offering provides a buying opportunity ahead of the company’s trial data releases. Citi notes BioMarin management stated that the financing is not intended to support any acquisitions in the near-term, and the firm keeps a Buy rating on the stock with a $49 price target.
Laboratory Corp. of America Holdings (NYSE:LH): After hosting meetings with management, Deutsche Bank believes that while LabCorp’s growth remains challenging, its 2012 guidance looks achievable. The firm lowered its price target for shares to $98 from $100 but maintains a Buy rating on the stock.
Ocz Technology Group Inc. (NASDAQ:OCZ): After meeting with OCZ Technology’s CFO Art Knapp, Piper Jaffray is more positive on shares and has more conviction in the company’s gross margin expansion opportunities. The firm reiterates an Overweight rating on OCZ with a $17 price target.
AstraZeneca PLC (NYSE:AZN): Leerink expects AstraZeneca (NYSE:AZN) to appoint a new CEO over the next six months and thinks the person should be aggressive on acquisitions. Leerink views Forest Labs (NYSE:FRX), a stock it upgraded this morning to Outperform, as the most logical takeover target for AstraZeneca, but feels the company has several reasonable options. Leerink lists Amylin (NASDAQ:AMLN) and Salix (NASDAQ:SLXP) as potential bolt-on acquisition candidates for AstraZeneca, and does not see Shire (NASDAQ:SHPGY) as a strong acquisition target without a substantial reduction in its assumed acquisition price. The firm sees little downside risk in shares of AstraZeneca barring a cut in the company’s dividend, but keeps a Market Perform rating on the stock.
Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.